(Yicai Global) Nov. 28 -- China's biggest genome sequencing firm BGI Genomics Co. [SHE:300676] has received inquiries from the Shenzhen Stock Exchange (SSE) over inconsistent production and sales data for reproductive health services for 2014 submitted during its initial public offering (IPO) application in 2015 and will be called on to answer a series of related questions, International Financial News reported on Saturday.

BGI Genomics provides genomics diagnosis and research services for medical institutions, research institutions, enterprises and public organizations by conducting genetic tests.

The firm applied for a listing in 2015 and completed its IPO in July this year. The company's share price has kept rising since its flotation, soaring from CNY46 apiece when it listed to as high as CNY260.

The documents state that BGI Genomics' production and sales of reproductive health services for 2014 was 515,600 and 515,600, respectively. However, these figures were scaled down to 425,100 and 425,100, respectively, in documents submitted in March this year, implying a decrease of 17.54 percent. Despite the differences, the company's operating income and profits remained changed.

BGI Genomics shares have fallen for three straight trading days and were down 8.35 percent at CNY190.81 yesterday.